Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CCR3 | P51677 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3479873 | 0.98 | KMT2A (0.51) | KMT2AMEN1CYP2C9CYP2C19CNR1 | |
| SCHEMBL3480121 | 0.93 | MEN1 (0.48) | KMT2AMEN1CYP2C9CYP2C19CNR1 | |
| SCHEMBL3480662 | 0.90 | CYP2C9 (0.52) | KMT2AMEN1CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL3480242 | 0.90 | KMT2A (0.49) | KMT2AMEN1CNR1CNR2ALDH1A1 | |
| SCHEMBL3479903 | 0.90 | KMT2A (0.53) | KMT2AMEN1CNR1CNR2ALDH1A1 | |
| SCHEMBL4189846 | 0.89 | MEN1 (0.46) | KMT2AMEN1CYP2C9CYP2C19GAA | |
| SCHEMBL3480208 | 0.89 | KMT2A (0.52) | KMT2AMEN1CNR1CNR2ALDH1A1 | |
| SCHEMBL4968951 | 0.88 | KMT2A (0.51) | KMT2AMEN1CNR1CNR2ALDH1A1 | |
| SCHEMBL3480097 | 0.88 | KMT2A (0.51) | KMT2AMEN1CNR1CNR2ALDH1A1 | |
| SCHEMBL3480164 | 0.88 | KMT2A (0.51) | KMT2AMEN1CNR1CNR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705052-B2 | Sulfonamide derivatives for the treatment of diabetes | MERCK SERONO SA (CH) | 2010-04-27 | — | — | US | claimed |
| US-20070043027-A1 | Sulfonamide derivatives for the treatment of diabetes | APPLIED RESERACH SYSTEMS ARS HOLDING N.V. (AN) | 2007-02-22 | — | — | US | claimed |
| US-20040077854-A1 | Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moietties as inhibitors of protein junkinases | MERCK SERONO SA (CH) | 2004-04-22 | — | — | US | claimed |
| EP-1322642-A2 | sHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES BEARING BOTH LIPOPHILIC AND IONISABLE MOIETIES AS INHIBITORS OF PROTEIN JUNKINASES | Applied Research Systems ARS Holding N.V. (AN) | 2003-07-02 | — | — | EP | claimed |
| WO-2002026733-A2 | sHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES BEARING BOTH LIPOPHILIC AND IONISABLE MOIETIES AS INHIBITORS OF PROTEIN JUNKINASES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2002-04-04 | — | — | WO | claimed |
| EP-1193268-A1 | Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of protein Junkinases | Applied Research Systems ARS Holding N.V. (AN) | 2002-04-03 | — | — | EP | claimed |
| US-8658640-B2 | JNK inhibitors for the treatment of endometriosis | MERCK SERONO SA (CH) | 2014-02-25 | — | — | US | disclosed |
| US-8592414-B2 | JNK inhibitors for the treatment of endometriosis | Merck Serono, S.A. (CH) | 2013-11-26 | — | — | US | disclosed |
| US-20130281447-A1 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | LABORATOIRES SERONO S.A. (CH) | 2013-10-24 | — | — | US | disclosed |
| US-20130267512-A1 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | LABORATOIRES SERONO S.A. (CH) | 2013-10-10 | — | — | US | disclosed |
| US-7705052-B2 | Sulfonamide derivatives for the treatment of diabetes | MERCK SERONO SA (CH) | 2010-04-27 | — | — | US | disclosed |
| US-20090176761-A1 | JNK Inhivitors for the Treatment of Endometriosis | LABORATORIES SERONO SA (CH) | 2009-07-09 | — | — | US | disclosed |
| US-20090176762-A1 | JNK Inhibitors for Treatment of Skin Diseases | LABORATOIRES SERONO SA (CH) | 2009-07-09 | — | — | US | disclosed |
| US-20080039377-A1 | Composition Comprising a Jnk Inhibitor and Cyclosporin | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2008-02-14 | — | — | US | disclosed |
| WO-2007141224-A2 | JNK INHIBITORS FOR TREATMENT OF SKIN DISEASES | LABORATOIRES SERONO SA (CH) | 2007-12-13 | — | — | WO | disclosed |
| US-20070043027-A1 | Sulfonamide derivatives for the treatment of diabetes | APPLIED RESERACH SYSTEMS ARS HOLDING N.V. (AN) | 2007-02-22 | — | — | US | disclosed |
| US-20040077854-A1 | Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moietties as inhibitors of protein junkinases | MERCK SERONO SA (CH) | 2004-04-22 | — | — | US | disclosed |
| EP-1322642-A2 | sHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES BEARING BOTH LIPOPHILIC AND IONISABLE MOIETIES AS INHIBITORS OF PROTEIN JUNKINASES | Applied Research Systems ARS Holding N.V. (AN) | 2003-07-02 | — | — | EP | disclosed |
| WO-2002026733-A2 | sHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES BEARING BOTH LIPOPHILIC AND IONISABLE MOIETIES AS INHIBITORS OF PROTEIN JUNKINASES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2002-04-04 | — | — | WO | disclosed |
| EP-1193268-A1 | Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of protein Junkinases | Applied Research Systems ARS Holding N.V. (AN) | 2002-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176762-A1 | JNK Inhibitors for Treatment of Skin Diseases | MAPKAPK2, JUN, MAP3K13 | KMT2A 2086/4885MEN1 4590/4885CYP2C9 4129/4885 |
| US-20040077854-A1 | Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moietties as inhibitors of protein junkinases | MAPK1, MAP3K1, MAPKAPK2 | KMT2A 1159/4885MEN1 2351/4885CYP2C9 1596/4885 |
| US-20070043027-A1 | Sulfonamide derivatives for the treatment of diabetes | CBR3, INSR, CS | KMT2A 2101/4885MEN1 3205/4885CYP2C9 1061/4885 |
| US-20080039377-A1 | Composition Comprising a Jnk Inhibitor and Cyclosporin | LCK, MAPKAPK2, MAP3K20 | KMT2A 3013/4885MEN1 1582/4885CYP2C9 3470/4885 |
| US-20130281447-A1 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | MAPKAPK2, MAPKAPK3, JUN | KMT2A 847/4885MEN1 3898/4885CYP2C9 4390/4885 |
| US-20090176761-A1 | JNK Inhivitors for the Treatment of Endometriosis | MAPKAPK2, MAP3K20, MAP3K6 | KMT2A 1484/4885MEN1 4390/4885CYP2C9 4437/4885 |
| US-20130267512-A1 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | MAPKAPK2, MAPKAPK3, JUN | KMT2A 847/4885MEN1 3898/4885CYP2C9 4390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.